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According to the Oxford Dictionaries Online, Medicine is “The science or practice of the diagnosis,
treatment, and prevention of disease.” This implies that a patient is in the central focus of the
profession and all relevant specializations and subareas are concerned with benefiting a patient’s
health. In recent years, the analysis of clinical and biomedical data, including high-throughput
experiments, has been added to the list of such specializations that make contributions for the
greater good. However, the analysis and the reuse of such data is in general difficult and for this
reason has been under scrutiny (Ioannidis, 2005; Chalmers and Glasziou, 2009; Ioannidis and
Khoury, 2011; Rung and Brazma, 2013; Ioannidis et al., 2015).
With breakthroughs in data production, the integration of unprecedentedly rich data is expected
to lead to an enormous impact on basic research and to translate on healthcare, but comes with
significant challenges for the practices of analysis, data sharing, and the evaluation of results (Marx,
2013; Fan et al., 2014; Emmert-Streib et al., 2016). Improvements in these areas would undoubtedly
make research process more efficient and its results more reliable. An important case is offered by
Baggerly and Coombes (2009) who found by the re-analysis of various data sets from Potti et al.
(2011) fundamental flaws leading ultimately in the discontinuation of three clinical cancer trials.
This became known as Duke Saga (Kolata, 2011). It is difficult to quantify their impact on the health
of patients but given they even identified erroneous therapeutic interventions based on the work
of Dr Potti, it is fair to assume that their work helped even saving the life of patients. Given this
contribution and its clearly beneficial impact for patients it is stunning that according to a recent
publication by Longo and Drazen (2016) scientists like Keith Baggerly and Kevin Coombes have
been pejoratively characterized as “research parasites.”
Regarding regulations for data sharing, a major point made in a series of papers published in the
New England Journal of Medicine (NEJM; Drazen, 2016; Longo and Drazen, 2016; Taichman et al.,
2016) was that
1. “Those using data collected by others should seek collaboration with those who collected the
data” (Taichman et al., 2016)
and
2. “Report the new findings with relevant coauthorship to acknowledge both the group that
proposed the new idea and the investigative group that accrued the data that allowed it to be
tested” (Longo and Drazen, 2016).
The initial reaction of the computational research community has not been positive (Berger et al.,
2016; McNutt, 2016).
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We are of the opinion that both suggestions are reasonable
as “can rules” if circumstances allow it, however, we think that
neither should be mandatory. The reason for this is simple. Let’s
say a published data set, and by this we mean a data set that
had to be made publicly available in order to publish major
findings in a journal or an obligation imposed by a funding
agency, is re-analyzed. In the following we call the scientists
generating the data “experimental party” and the scientists
re-analyzing the data “computational party.” There are three
possible outcomes. First, no results are found which means
nothing needs to be published. Second, results are found and
both parties are happy with the conclusions. In this case the
results can be published and the experimental party could be
offered coauthorship but only if the usual criteria for receiving an
authorship are met, requiring a significant contribution beyond
merely providing the data. Third, results are found but both
parties disagree with the conclusions. This is certainly the most
interesting outcome that deserves attention and is also the case
in the Duke Saga. The problem with requiring to name the
experimental party as coauthors could be a conflict of interests
preventing a paper even from being submitted to a journal for
review. Hence, there would be a leverage one would give to such
authors allowing to at least delay such a submission indefinitely.
For instance, we could ask ourselves at what time point after
the accusation made by Keith Baggerly and Kevin Coombes
would Anil Potti have agreed to be a coauthor on the paper in
Baggerly and Coombes (2009)? The answer to this question is
unknown, however, it is not difficult to see the problems that
are implied by such a “must” rule that are clearly not beneficial
for the patients enrolled in clinical trials based on flawed
benefits.
From the outline of these problems, we suggest the following
rules for data sharing:
Mandatory rules:
M1 In the publication of an article re-analyzing published data,
add a citation to the original publication(s) of the data.
M2 A possible communication with the experimental party
should be acknowledged in the published article.
M3 The code used for re-analyzing the data should be made
publicly available.
Optional rule:
O1 If the computational and the experimental parties agree
on the research findings declaring no conflict of interest
and the experimental party contributes significantly to the
re-analysis, both parties should receive authorship.
In addition to this, we consider it obligatory for journals
publishing articles to turn out being erroneous that they
publish the articles revealing these issues. For instance,
Anil Potti had to retract papers published in Nature and
Science but the paper by Keith Baggerly and Kevin Coombes
wasn’t accepted there, instead, it appeared in the Annal of
Applied Statistics (Baggerly and Coombes, 2009). This is not
acceptable!
The above rules M1–M3 will ensure that it is possible that the
re-analysis of data can “disprove what the original investigators
had posited” (Longo and Drazen, 2016) because if the initial
analysis is wrong this needs to be revealed without any hesitation
or qualification.
From a more fundamental point of view the above question of
data sharing has an analogy with capitalism. The reason for this is
that in capitalism the capital (money) can generate more capital
without labor by means of interests. In our case the new capital
is data which, according to the rules suggested by Longo and
Drazen (2016), Drazen (2016), and Taichman et al. (2016), can
generate authorship(s) without contributing to the re-analysis of
data ad infimum. As such it would change the way we know
science completely. That means the question we need to ask
ourselves is do we want a dataism (Lohr, 2015) in science that
allows such a monopoly?We are strictly against such a monopoly
based on data and for this reason suggested publication rules that
prevent this from happening and plead for a data sharing with
“research parasites” in the interest of the patients from whom the
data originate.
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